US biotech Celgene (Nasdaq: CELG) became the first drugmaker of 2018 to announce an acquisition worth more than $1 billion on Sunday with news that it is to buy Impact Biomedicines.
Celgene will pay approximately $1.1 billion upfront to acquire the San Diego-based start-up, which is developing fedratinib for myelofibrosis and polycythemia vera.
"We believe fedratinib is uniquely positioned as a potential treatment for myelofibrosis and it provides strategic options for us to build leadership in this disease with luspatercept and other pipeline assets"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze